Enrofloxacin, a fluoroquinolone antibiotic used in veterinary medicine, was developed in the late 1970s and approved for use in the 1980s. Its history is marked by its effectiveness against a broad spectrum of bacterial infections in animals, including respiratory, urinary, and gastrointestinal infections. Enrofloxacin’s development included extensive clinical trials in livestock and companion animals, and its approval was accompanied by careful monitoring of potential adverse effects, such as cartilage toxicity in young animals. The drug is widely used in veterinary practice and is often incorporated into combination therapies for complex infections. Its usage guidelines emphasize appropriate dosing and caution to prevent antimicrobial resistance.
BRAND NAMES
Baytril – the most widely recognized brand, originally by Bayer
Enrocin – another veterinary formulation
Flobac – used in some regions for livestock
- Enrovet – veterinary-specific formulations
MECHANISM OF ACTION
Enrofloxacin is a fluoroquinolone antibiotic that exerts its bactericidal effect by inhibiting key bacterial enzymes involved in DNA replication. Specifically, it targets DNA gyrase (topoisomerase II) and topoisomerase IV, which are essential for supercoiling and uncoiling bacterial DNA during replication and transcription.
PHARMACOKINETICS
Absorption
Enrofloxacin is well absorbed following oral, subcutaneous, or intramuscular administration in animals. After oral dosing, it exhibits moderate to high bioavailability, although the exact percentage can vary depending on the species and formulation.
Distribution
Enrofloxacin has a moderate volume of distribution, generally ranging from 1–2 L/kg in most animal species, indicating that the drug distributes well into body tissues and fluids beyond the bloodstream.
Metabolism
Enrofloxacin is partially metabolized in the liver to its primary active metabolite, ciprofloxacin, which retains antibacterial activity. The extent of metabolism varies between species; for example, dogs convert a smaller proportion to ciprofloxacin compared to cats or cattle.
Elimination
Enrofloxacin is primarily eliminated via renal excretion, with a portion also excreted in the bile and feces. Both the parent drug and its active metabolite, ciprofloxacin, are excreted in urine, contributing to its effectiveness in treating urinary tract infections. The elimination half-life varies among species, generally ranging from 4 to 12 hours, allowing for once- or twice-daily dosing in most animals.
PHARMACODYNAMICS
Enrofloxacin exhibits concentration-dependent bactericidal activity, meaning its effectiveness increases with higher drug concentrations relative to the bacterial minimum inhibitory concentration (MIC). It acts by inhibiting DNA gyrase and topoisomerase IV, which prevents bacterial DNA replication and leads to cell death.
ADMINISTRATION
Enrofloxacin is administered via oral, subcutaneous, or intramuscular routes, depending on the species and type of infection. Oral formulations, often in the form of tablets, solutions, or medicated feed, are commonly used for companion animals and livestock, while injectable forms are preferred for rapid systemic effect or when oral administration is impractical.
DOSAGE AND STRENGTH
Enrofloxacin is available in various strengths and formulations, including oral tablets, oral solutions, and injectable solutions, to accommodate different species and treatment needs.
DRUG INTERACTIONS
Enrofloxacin can interact with several drugs, which may alter its effectiveness or increase the risk of adverse effects. Cation-containing compounds such as antacids, sucralfate, or mineral supplements (calcium, magnesium, aluminum, or iron) can bind enrofloxacin in the gastrointestinal tract, reducing its absorption.
FOOD INTERACTIONS
Enrofloxacin absorption can be slightly affected by food, but its clinical efficacy is generally not significantly reduced when administered with meals. High-calcium or mineral-rich diets, including dairy products or fortified feeds, may bind the drug in the gastrointestinal tract, decreasing its absorption and plasma concentrations.
CONTRAINDICATIONS
Enrofloxacin is contraindicated in animals with a known hypersensitivity to fluoroquinolones, as allergic reactions can range from mild skin reactions to severe anaphylaxis. It should not be used in growing puppies, kittens, or other young animals due to the risk of articular cartilage damage and joint disorders.
SIDE EFFECTS
Gastrointestinal: vomiting, diarrhea, decreased appetite
Musculoskeletal: cartilage damage in growing animals, lameness
Neurological: tremors, seizures, behavioral changes (rare)
Allergic reactions: skin rash, swelling, hypersensitivity (rare)
Hepatic or renal effects: possible in animals with preexisting liver or kidney disease
Long-term use: increased risk of antimicrobial resistance.
TOXICITY
Enrofloxacin toxicity is relatively uncommon when used at therapeutic doses but can occur with overdose or prolonged administration. Toxic effects primarily affect the musculoskeletal and nervous systems. In young or growing animals, excessive doses may cause permanent cartilage damage and joint disorders, leading to lameness.
